These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10147004)

  • 1. The economics of screening for measles.
    Sellick JA
    Pharmacoeconomics; 1992 Dec; 2(6):440-3. PubMed ID: 10147004
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
    Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
    Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program.
    Babigumira JB; Levin A; Burgess C; Garrison LP; Bauch CT; Braka F; Mbabazi WB; Nabyonga JO; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S116-23. PubMed ID: 21666152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing measles with previous eradication programs: enabling and constraining factors.
    Keegan R; Dabbagh A; Strebel PM; Cochi SL
    J Infect Dis; 2011 Jul; 204 Suppl 1():S54-61. PubMed ID: 21666211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the benefits of increasing measles immunization rates.
    Zwanziger J; Szilagyi PG; Kaul P
    Health Serv Res; 2001 Oct; 36(5):885-909. PubMed ID: 11666109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
    Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
    PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The average cost of measles cases and adverse events following vaccination in industrialised countries.
    Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
    BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of measles elimination activities on immunization services and health systems: findings from six countries.
    Hanvoravongchai P; Mounier-Jack S; Oliveira Cruz V; Balabanova D; Biellik R; Kitaw Y; Koehlmoos T; Loureiro S; Molla M; Nguyen H; Ongolo-Zogo P; Sadykova U; Sarma H; Teixeira M; Uddin J; Dabbagh A; Griffiths UK
    J Infect Dis; 2011 Jul; 204 Suppl 1():S82-9. PubMed ID: 21666218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future savings from measles eradication in industrialized countries.
    Carabin H; Edmunds WJ
    J Infect Dis; 2003 May; 187 Suppl 1():S29-35. PubMed ID: 12721889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of prevaccination screening of health care workers for immunity to measles, rubella and mumps.
    Ferson MJ; Robertson PW; Whybin LR
    Med J Aust; 1994 Apr; 160(8):478-82. PubMed ID: 8170422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of measles treatment: a systematic review.
    Vo NX; Van Nguyen AT; Mai Tran HT; Thuy Truong LT; Bao Nguyen NN
    J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S148-S154. PubMed ID: 31369545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Estimates of Crude and Effective Coverage of Measles Immunization in Low-Resource Settings: Findings from Salud Mesoamérica 2015.
    Colson KE; Zúñiga-Brenes P; Ríos-Zertuche D; Conde-Glez CJ; Gagnier MC; Palmisano E; Ranganathan D; Usmanova G; Salvatierra B; Nazar A; Tristao I; Sanchez Monin E; Anderson BW; Haakenstad A; Murphy T; Lim S; Hernandez B; Lozano R; Iriarte E; Mokdad AH
    PLoS One; 2015; 10(7):e0130697. PubMed ID: 26136239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of supplementary immunization for measles in India.
    Dabral M
    Indian Pediatr; 2009 Nov; 46(11):957-62. PubMed ID: 19578225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost analysis of measles in refugees arriving at Los Angeles International Airport from Malaysia.
    Coleman MS; Burke HM; Welstead BL; Mitchell T; Taylor EM; Shapovalov D; Maskery BA; Joo H; Weinberg M
    Hum Vaccin Immunother; 2017 May; 13(5):1084-1090. PubMed ID: 28068211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global eradication of measles: an epidemiologic and economic evaluation.
    Levin A; Burgess C; Garrison LP; Bauch C; Babigumira J; Simons E; Dabbagh A
    J Infect Dis; 2011 Jul; 204 Suppl 1():S98-106. PubMed ID: 21666220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in measles control: Zambia, 1999-2004.
    Wkly Epidemiol Rec; 2005 Jun; 80(24):213-7. PubMed ID: 16042096
    [No Abstract]   [Full Text] [Related]  

  • 17. Economic analysis of the 1996-1997 mass measles immunization campaigns in South Africa.
    Uzicanin A; Zhou F; Eggers R; Webb E; Strebel P
    Vaccine; 2004 Sep; 22(25-26):3419-26. PubMed ID: 15308367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Review of the 2016 Swiss immunization schedule and technology update for improving vaccine management].
    Diana A
    Rev Med Suisse; 2016 May; 12(518):949-53. PubMed ID: 27352591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mounting a good offense against measles.
    Orenstein W; Seib K
    N Engl J Med; 2014 Oct; 371(18):1661-3. PubMed ID: 25354100
    [No Abstract]   [Full Text] [Related]  

  • 20. Beyond vertical and horizontal programs: a diagonal approach to building national immunization programs through measles elimination.
    Orenstein WA; Seib K
    Expert Rev Vaccines; 2016 Jul; 15(7):791-3. PubMed ID: 26967373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.